微生物試劑 抗-PD-L1抗體，克隆5H1

微生物試劑 抗-PD-L1抗體，克隆5H1

常見的描繪

歐式(shi)風格性(xing)生(sheng)(sheng)(sheng)殖(zhi)(zhi)(zhi)人(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)體(ti)(ti)(ti)(ti)(ti)癌(ai)人(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)體(ti)(ti)(ti)(ti)(ti)神(shen)(shen)經(jing)(jing)(jing)(jing)元(yuan)(yuan)滅亡(wang)(wang)1配(pei)(pei)(pei)體(ti)(ti)(ti)(ti)(ti)1（UniProt Q9NZQ7；也(ye)稱(cheng)之為B7-H1、B7同(tong)系物1、CD274、PD-L1、PDCD1配(pei)(pei)(pei)體(ti)(ti)(ti)(ti)(ti)1、歐式(shi)風格性(xing)滅亡(wang)(wang)配(pei)(pei)(pei)體(ti)(ti)(ti)(ti)(ti)1）由人(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)的(de)(de)CD274（也(ye)稱(cheng)之為B7H1、PDCD1L1、PDCD1LG1、PDL1）染(ran)色體(ti)(ti)(ti)(ti)(ti)（染(ran)色體(ti)(ti)(ti)(ti)(ti)ID 29126）編號(hao)。PD-L1一(yi)(yi)(yi)種累計跨膜的(de)(de)I型膜卵白(bai)，在(zai)勾引和(he)(he)堅持對自(zi)身(shen)的(de)(de)免疫人(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)體(ti)(ti)(ti)(ti)(ti)癌(ai)人(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)體(ti)(ti)(ti)(ti)(ti)神(shen)(shen)經(jing)(jing)(jing)(jing)元(yuan)(yuan)接受中(zhong)起(qi)關(guan)(guan)頭作(zuo)用。它在(zai)純化的(de)(de)T生(sheng)(sheng)(sheng)殖(zhi)(zhi)(zhi)人(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)體(ti)(ti)(ti)(ti)(ti)癌(ai)人(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)體(ti)(ti)(ti)(ti)(ti)神(shen)(shen)經(jing)(jing)(jing)(jing)元(yuan)(yuan)和(he)(he)B生(sheng)(sheng)(sheng)殖(zhi)(zhi)(zhi)人(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)體(ti)(ti)(ti)(ti)(ti)癌(ai)人(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)體(ti)(ti)(ti)(ti)(ti)神(shen)(shen)經(jing)(jing)(jing)(jing)元(yuan)(yuan)、樹(shu)突狀生(sheng)(sheng)(sheng)殖(zhi)(zhi)(zhi)人(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)體(ti)(ti)(ti)(ti)(ti)癌(ai)人(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)體(ti)(ti)(ti)(ti)(ti)神(shen)(shen)經(jing)(jing)(jing)(jing)元(yuan)(yuan)、角(jiao)質組(zu)成(cheng)部分生(sheng)(sheng)(sheng)殖(zhi)(zhi)(zhi)人(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)體(ti)(ti)(ti)(ti)(ti)癌(ai)人(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)體(ti)(ti)(ti)(ti)(ti)神(shen)(shen)經(jing)(jing)(jing)(jing)元(yuan)(yuan)和(he)(he)四核cpu生(sheng)(sheng)(sheng)殖(zhi)(zhi)(zhi)人(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)體(ti)(ti)(ti)(ti)(ti)癌(ai)人(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)體(ti)(ti)(ti)(ti)(ti)神(shen)(shen)經(jing)(jing)(jing)(jing)元(yuan)(yuan)上表(biao)達(da)(da)(da)。在(zai)心(xin)理、骨格肌、胚胎(tai)和(he)(he)肺中(zhong)也(ye)報道范文(wen)了較高的(de)(de)表(biao)達(da)(da)(da)。PD-1和(he)(he)PD-1配(pei)(pei)(pei)體(ti)(ti)(ti)(ti)(ti)1和(he)(he)2（PD-L1和(he)(he)PD-L2）是冶療T生(sheng)(sheng)(sheng)殖(zhi)(zhi)(zhi)人(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)體(ti)(ti)(ti)(ti)(ti)癌(ai)人(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)體(ti)(ti)(ti)(ti)(ti)神(shen)(shen)經(jing)(jing)(jing)(jing)元(yuan)(yuan)純化和(he)(he)外周(zhou)接受的(de)(de)B7:CD28家(jia)屬親人(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)全體(ti)(ti)(ti)(ti)(ti)成(cheng)員。當與TCR聯系時(shi)，PD-1與其(qi)說配(pei)(pei)(pei)體(ti)(ti)(ti)(ti)(ti)的(de)(de)真(zhen)正的(de)(de)愛(ai)情作(zuo)用向T生(sheng)(sheng)(sheng)殖(zhi)(zhi)(zhi)人(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)體(ti)(ti)(ti)(ti)(ti)癌(ai)人(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)體(ti)(ti)(ti)(ti)(ti)神(shen)(shen)經(jing)(jing)(jing)(jing)元(yuan)(yuan)繁殖(zhi)(zhi)(zhi)和(he)(he)生(sheng)(sheng)(sheng)殖(zhi)(zhi)(zhi)人(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)體(ti)(ti)(ti)(ti)(ti)癌(ai)人(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)體(ti)(ti)(ti)(ti)(ti)神(shen)(shen)經(jing)(jing)(jing)(jing)元(yuan)(yuan)內部會產(chan)生(sheng)(sheng)(sheng)通知抑制旌旗燈(deng)號(hao)。即(ji)使PD-L1在(zai)造血和(he)(he)非(fei)造血生(sheng)(sheng)(sheng)殖(zhi)(zhi)(zhi)人(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)體(ti)(ti)(ti)(ti)(ti)癌(ai)人(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)體(ti)(ti)(ti)(ti)(ti)神(shen)(shen)經(jing)(jing)(jing)(jing)元(yuan)(yuan)中(zhong)普(pu)及表(biao)達(da)(da)(da)，但PD-L2的(de)(de)表(biao)達(da)(da)(da)間距(ju)包(bao)括(kuo)但不限于抗原(yuan)呈遞生(sheng)(sheng)(sheng)殖(zhi)(zhi)(zhi)人(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)體(ti)(ti)(ti)(ti)(ti)癌(ai)人(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)體(ti)(ti)(ti)(ti)(ti)神(shen)(shen)經(jing)(jing)(jing)(jing)元(yuan)(yuan)(APC)，包(bao)羅樹(shu)突狀生(sheng)(sheng)(sheng)殖(zhi)(zhi)(zhi)人(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)體(ti)(ti)(ti)(ti)(ti)癌(ai)人(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)體(ti)(ti)(ti)(ti)(ti)神(shen)(shen)經(jing)(jing)(jing)(jing)元(yuan)(yuan)(DC)和(he)(he)巨噬生(sheng)(sheng)(sheng)殖(zhi)(zhi)(zhi)人(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)體(ti)(ti)(ti)(ti)(ti)癌(ai)人(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)體(ti)(ti)(ti)(ti)(ti)神(shen)(shen)經(jing)(jing)(jing)(jing)元(yuan)(yuan)。PD-1信(xin)號(hao)徑路在(zai)急(ji)慢性(xing)HIV轉(zhuan)染(ran)性(xing)21世紀滯后效應(ying)T生(sheng)(sheng)(sheng)殖(zhi)(zhi)(zhi)人(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)體(ti)(ti)(ti)(ti)(ti)癌(ai)人(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)體(ti)(ti)(ti)(ti)(ti)神(shen)(shen)經(jing)(jing)(jing)(jing)元(yuan)(yuan)克服的(de)(de)進行性(xing)折損中(zhong)起(qi)關(guan)(guan)頭作(zuo)用。在(zai)一(yi)(yi)(yi)些周(zhou)圍環境下，阻(zu)隔該信(xin)號(hao)徑路才能(neng)規復無數(shu)T生(sheng)(sheng)(sheng)殖(zhi)(zhi)(zhi)人(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)體(ti)(ti)(ti)(ti)(ti)癌(ai)人(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)體(ti)(ti)(ti)(ti)(ti)神(shen)(shen)經(jing)(jing)(jing)(jing)元(yuan)(yuan)好處。PD-L1最終以旌旗燈(deng)號(hao)肽（aa 1-18）編碼(ma)序列(lie)會產(chan)生(sheng)(sheng)(sheng)，最后將(jiang)其(qi)割孔(kong)以會產(chan)生(sheng)(sheng)(sheng)必(bi)備條(tiao)件大的(de)(de)生(sheng)(sheng)(sheng)殖(zhi)(zhi)(zhi)人(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)體(ti)(ti)(ti)(ti)(ti)癌(ai)人(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)(ren)體(ti)(ti)(ti)(ti)(ti)神(shen)(shen)經(jing)(jing)(jing)(jing)元(yuan)(yuan)外（aa 19-238）東南部的(de)(de)心(xin)智(zhi)成(cheng)熟(shu)卵白(bai)，該東南部包(bao)羅一(yi)(yi)(yi)家(jia)Ig樣V型頁面構造域（aa 19-127）和(he)(he)一(yi)(yi)(yi)家(jia)Ig樣C2型頁面構造域（aa 133-225），最后一(yi)(yi)(yi)家(jia)跨膜頁面構造域（aa 239-259）和(he)(he)一(yi)(yi)(yi)家(jia)胞質尾區（aa 260-290）。

特同性戀

克隆5H1可驗測(ce)人歐(ou)式性神經(jing)內(nei)(nei)部滅亡配體1（PD-L1）。其靶向(xiang)療法神經(jing)內(nei)(nei)部外頁面布局域中的表(biao)位。

免役原

起點(dian)終點(dian)人合拼PD-L1。

表位：胞外域

用

抗體節(jie)(jie)構藥劑(ji)學式(shi)（白臘(la)）闡發：一款代表英語性(xing)批號在(zai)抗體節(jie)(jie)構藥劑(ji)學式(shi)根據(ju)中檢(jian)查測量到(dao)PD-L1（Bigelow，E.，et. al.（2013）.J Vis Exp.3;(71); Spranger, S., et. al. (2013).Sci Transl Med. 5(200):200ra116; Parra, E.R., et. al. (2018).Appl Immunohistochem Mol Morphol.26(2):83-93; Andorsky, D.J., et. al. (2011).Clin Cancer Res. 17(13):4232-44; Sunshine, J.C., et. al. (2017).Clin Cancer Res. 23（16）:4938-4944）。

卵(luan)(luan)白(bai)質痕跡闡發：一位代(dai)表英語(yu)性(xing)批號(hao)在卵(luan)(luan)白(bai)質痕跡法使用中測量(liang)到PD-L1（Parra，E.R.，et. al.（2018）.Appl Immunohistochem.Mol.Morphol.26（2）:83-93。

抗(kang)PD-L1，克隆(long)5H1，目次號MABC1115有(you)的是種(zhong)可驗測PD-L1的小(xiao)鼠(shu)單(dan)克隆(long)抵抗(kang)能力，并已審單(dan)可作于(yu)免(mian)役(yi)檢(jian)測體細(xi)胞藥劑學、免(mian)役(yi)檢(jian)測連接結構藥劑學（白(bai)臘）和卵白(bai)質印記。

專題研討種別

組(zu)織(zhi)細胞凋亡 & 肝癌

高品質

所經操作過程(cheng)天然免疫腫瘤(liu)(liu)細胞膜(mo)藥劑學在(zai)MDA-MB-231腫瘤(liu)(liu)細胞膜(mo)中終止(zhi)判斷(duan)。

免疫表(biao)面(mian)抗(kang)原組織神(shen)(shen)經(jing)元檢(jian)查是否闡(chan)發：該表(biao)面(mian)抗(kang)原以1:50濃縮咖啡(fei)度可在MDA-MB-231組織神(shen)(shen)經(jing)元中驗測(ce)到PD-L1。

政策刻畫

算(suan)計份子量(liang)33.28 kDa。

款式

事態：純化

純(chun)化的(de)小鼠單克隆抗體陽性IgG1，溶水(shui)含有疊(die)氮化物的(de)PBS中。

純化卵白G

儲藏及不減性

自接(jie)受(shou)生(sheng)效日(ri)起(qi)在(zai)-20°C可(ke)以(yi)(yi)變儲放(fang)在(zai)一年(nian)。妥善處理倡儀書：接(jie)受(shou)后，在(zai)拆下(xia)蓋子以(yi)(yi)往，將(jiang)小(xiao)瓶離(li)心力(li)(li)分(fen)離(li)并漸漸摻雜液體。預(yu)包裝(zhuang)至微量分(fen)析離(li)心力(li)(li)分(fen)離(li)管(guan)上，并存放(fang)于-20°C。阻止平繁凍融宿命，不燃要毀(hui)掉IgG并反應化(hua)合物功(gong)能。

同樣聲明函

密度：請符合相應院校代號的動態數據表。

免責聲明函

除了讓我(wo)(wo)們的(de)(de)(de)目次或(huo)(huo)物品隨附的(de)(de)(de)任意子(zi)公司(si)材(cai)料中(zhong)還要(yao)聲明范(fan)文，要(yao)不(bu)然讓我(wo)(wo)們的(de)(de)(de)物品預期收(shou)益僅(jin)廣(guang)泛用到(dao)討論優(you)點，不(bu)能廣(guang)泛用到(dao)其他任意受眾，包羅但不(bu)僅(jin)為未經授權受權的(de)(de)(de)商(shang)業貿(mao)易優(you)點、離(li)體(ti)診(zhen)治優(you)點、離(li)體(ti)或(huo)(huo)里面根治優(you)點或(huo)(huo)對人類(lei)或(huo)(huo)常綠(lv)植物的(de)(de)(de)其他案例的(de)(de)(de)要(yao)花費或(huo)(huo)采取。